0000899243-21-024532.txt : 20210617
0000899243-21-024532.hdr.sgml : 20210617
20210617195640
ACCESSION NUMBER: 0000899243-21-024532
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210615
FILED AS OF DATE: 20210617
DATE AS OF CHANGE: 20210617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aivado Manuel
CENTRAL INDEX KEY: 0001709603
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38130
FILM NUMBER: 211026638
MAIL ADDRESS:
STREET 1: C/O AILERON THERAPEUTICS, INC.
STREET 2: 281 ALBANY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC
CENTRAL INDEX KEY: 0001420565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 285 SUMMER STREET
STREET 2: UNIT 101
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 617-995-0900
MAIL ADDRESS:
STREET 1: 285 SUMMER STREET
STREET 2: UNIT 101
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-15
0
0001420565
AILERON THERAPEUTICS INC
ALRN
0001709603
Aivado Manuel
C/O AILERON THERAPEUTICS, INC.
285 SUMMER STREET, SUITE 101
BOSTON
MA
02210
1
1
0
0
See Remarks
Stock Option (right to buy)
1.29
2021-06-15
4
A
0
2440000
0.00
A
2031-06-14
Common Stock
2440000
2440000
D
This option was granted on June 15, 2021. The shares underlying the option are scheduled to vest as to 25% of the shares on June 15, 2022 and thereafter in equal monthly installments through June 15, 2025.
President and Chief Executive Officer
/s/ Richard Wanstall, attorney-in-fact for Manuel Aivado
2021-06-17